[
  {
    "title": "富士莱(301258.SZ)：拟将部分募投项目结项、终止 并将节余募资投入新项目及永久补流",
    "href": "http://stock.jrj.com.cn/2022/12/14200637213046.shtml",
    "datetime": "2022-12-14 20:06:21",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)第三季度净利3713.35万元 同比增长60.07%",
    "href": "http://stock.jrj.com.cn/2022/10/25190837082724.shtml",
    "datetime": "2022-10-25 19:08:49",
    "code": "301258"
  },
  {
    "title": "富士莱：目前在手订单充足 产能利用率较高",
    "href": "http://stock.jrj.com.cn/2022/09/28193637028560.shtml",
    "datetime": "2022-09-28 19:36:45",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)：118.41万股首发网下配售限售股9月29日解禁",
    "href": "http://stock.jrj.com.cn/2022/09/26185937022556.shtml",
    "datetime": "2022-09-26 18:59:45",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)半年度净利润9000.03万元、同比增长42.90%",
    "href": "http://stock.jrj.com.cn/2022/08/22202336922928.shtml",
    "datetime": "2022-08-22 20:23:45",
    "code": "301258"
  },
  {
    "title": "富士莱：目前疫情总体对公司生产经营影响不大",
    "href": "http://stock.jrj.com.cn/2022/08/04165036870522.shtml",
    "datetime": "2022-08-04 16:50:15",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)：以3000万元设苏州鲲泰生物科技",
    "href": "http://stock.jrj.com.cn/2022/07/20200736829689.shtml",
    "datetime": "2022-07-20 20:07:24",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)：以3000万元设苏州贝格致远投资、全面聚焦于生物医药领域",
    "href": "http://stock.jrj.com.cn/2022/07/20200636829693.shtml",
    "datetime": "2022-07-20 20:06:12",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)2021年度权益分派10派4元 股权登记日为6月7日",
    "href": "http://stock.jrj.com.cn/2022/05/31165436693492.shtml",
    "datetime": "2022-05-31 16:54:31",
    "code": "301258"
  },
  {
    "title": "富士莱2022年第一季度净利3991.94万同比增长48.5% 政府补助增加",
    "href": "http://stock.jrj.com.cn/2022/05/04115036554813.shtml",
    "datetime": "2022-05-04 11:50:59",
    "code": "301258"
  },
  {
    "title": "富士莱2021年净利1.2亿同比下滑14.78% 董事长钱祥云薪酬80.63万",
    "href": "http://stock.jrj.com.cn/2022/04/26221336479045.shtml",
    "datetime": "2022-04-26 22:13:13",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)2021年度净利润降14.78%至1.2亿元 拟10派4元",
    "href": "http://stock.jrj.com.cn/2022/04/26194436478045.shtml",
    "datetime": "2022-04-26 19:44:06",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)一季度净利润3991.94万元 同比增长48.50%",
    "href": "http://stock.jrj.com.cn/2022/04/26194136478048.shtml",
    "datetime": "2022-04-26 19:41:50",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)：“年产720吨医药中间体及原料药扩建项目”结项",
    "href": "http://stock.jrj.com.cn/2022/04/12162636315549.shtml",
    "datetime": "2022-04-12 16:26:00",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)：拟使用不超9900万元超募资金永久补充流动资金",
    "href": "http://stock.jrj.com.cn/2022/04/12162536315550.shtml",
    "datetime": "2022-04-12 16:25:34",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)：拟使用不超4亿元闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/04/12162436315553.shtml",
    "datetime": "2022-04-12 16:24:18",
    "code": "301258"
  },
  {
    "title": "【龙虎榜】富士莱3月29日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/03/29180336151047.shtml",
    "datetime": "2022-03-29 18:03:31",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)将于3月29日在深交所上市",
    "href": "http://stock.jrj.com.cn/2022/03/27173235593080.shtml",
    "datetime": "2022-03-27 17:32:18",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)披露上市发行结果：遭弃购7.715万股 由联席主承销商包销",
    "href": "http://stock.jrj.com.cn/2022/03/22210434862328.shtml",
    "datetime": "2022-03-22 21:04:04",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)中签号出炉：中签号码共有2.22万个",
    "href": "http://stock.jrj.com.cn/2022/03/20172934852212.shtml",
    "datetime": "2022-03-20 17:29:00",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)IPO定价为48.30元/股 3月17日申购",
    "href": "http://stock.jrj.com.cn/2022/03/15210934831003.shtml",
    "datetime": "2022-03-15 21:09:46",
    "code": "301258"
  },
  {
    "title": "富士莱(301258.SZ)：网上路演时间为3月16日14:00-16:00",
    "href": "http://stock.jrj.com.cn/2022/03/14204734825820.shtml",
    "datetime": "2022-03-14 20:47:45",
    "code": "301258"
  },
  {
    "title": "富士莱：盈利持续恶化 募资或被闲置",
    "href": "http://stock.jrj.com.cn/ipo/2022/03/08162234541414.shtml",
    "datetime": "2022-03-08 16:22:58",
    "code": "301258"
  },
  {
    "title": "富士莱过会：今年IPO过关第329家 东方投行过5单",
    "href": "http://stock.jrj.com.cn/2021/09/30100633541403.shtml",
    "datetime": "2021-09-30 10:06:00",
    "code": "301258"
  },
  {
    "title": "东利机械、富士莱、华融化学9月29日创业板首发上会",
    "href": "http://stock.jrj.com.cn/2021/09/23161233504797.shtml",
    "datetime": "2021-09-23 16:12:00",
    "code": "301258"
  },
  {
    "title": "富士莱二闯IPO净利陡降30% 高度依赖贸易商营收占比超六成",
    "href": "http://stock.jrj.com.cn/ipo/2021/08/27074233330459.shtml",
    "datetime": "2021-08-27 07:42:36",
    "code": "301258"
  },
  {
    "title": "富士莱二闯IPO净利陡降30% 高度依赖贸易商营收占比超六成",
    "href": "http://stock.jrj.com.cn/ipo/2021/08/27074233425010.shtml",
    "datetime": "2021-08-27 07:42:36",
    "code": "301258"
  },
  {
    "title": "富士莱二闯IPO净利陡降30% 高度依赖贸易商营收占比超六成",
    "href": "http://stock.jrj.com.cn/ipo/2021/08/27074233449128.shtml",
    "datetime": "2021-08-27 07:42:36",
    "code": "301258"
  },
  {
    "title": "富士莱二闯IPO净利陡降30% 高度依赖贸易商营收占比超六成",
    "href": "http://stock.jrj.com.cn/ipo/2021/08/27074233436370.shtml",
    "datetime": "2021-08-27 07:42:36",
    "code": "301258"
  },
  {
    "title": "外销占比超七成 募资6.70亿元拟用于产能扩建和研发中心建设 富士莱创业板IPO获受理 | 产业新股",
    "href": "http://stock.jrj.com.cn/2020/11/13180831276681.shtml",
    "datetime": "2020-11-13 18:08:25",
    "code": "301258"
  },
  {
    "title": "富士莱医药IPO：上半年毛利率下滑 存产品结构单一等风险",
    "href": "http://stock.jrj.com.cn/ipo/2018/10/22133325352759.shtml",
    "datetime": "2018-10-22 13:33:00",
    "code": "301258"
  },
  {
    "title": "富士莱医药IPO：上半年毛利率下滑 存产品结构单一等风险",
    "href": "http://stock.jrj.com.cn/ipo/2018/10/22133325325950.shtml",
    "datetime": "2018-10-22 13:33:00",
    "code": "301258"
  },
  {
    "title": "富士莱医药IPO：上半年毛利率下滑 存产品结构单一等风险",
    "href": "http://stock.jrj.com.cn/ipo/2018/10/22133325418470.shtml",
    "datetime": "2018-10-22 13:33:00",
    "code": "301258"
  },
  {
    "title": "富士莱医药IPO：上半年毛利率下滑 存产品结构单一等风险",
    "href": "http://stock.jrj.com.cn/ipo/2018/10/22133325239565.shtml",
    "datetime": "2018-10-22 13:33:00",
    "code": "301258"
  },
  {
    "title": "富士莱发布2016年年度报告，报告期年度实现营业收入32150万元",
    "href": "http://stock.jrj.com.cn/2018/03/26182524300287.shtml",
    "datetime": "2018-03-26 18:25:48",
    "code": "301258"
  },
  {
    "title": "富士莱上市申请获证监会受理 股票暂停转让",
    "href": "http://stock.jrj.com.cn/2017/07/03100622687120.shtml",
    "datetime": "2017-07-03 10:06:45",
    "code": "301258"
  }
]